Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2026.117036 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Simona Casalino und 13 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy; Centro Ricerche Cliniche, Verona, Italy. Hauptthemen laut MEDLINE: Bile Duct Neoplasms, Cholangiocarcinoma, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, NextGenerationEU.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy; Centro Ricerche Cliniche, Verona, Italy.
- Digestive Molecular Clinical Oncology Research Unit, University of Verona, Verona, Italy.
- Department of Oncology, University College Hospital, London, UK.
- Department of Gastroenterology, Hepatology , Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Centro Ricerche Cliniche, Verona, Italy.
- Department of Oncology, San Bortolo General Hospital, Azienda ULSS8 Berica, Vicenza, Italy.
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- NextGenerationEU
Zitieren
APA
Casalino, S., Scarlato, E., Cruz, M. C., Gerdes, C., Sordo, A., Quinzii, A., Zecchetto, C., Messineo, L., Tasselli, E., Mendo, L., Saborowski, A., Bridgewater, J., Vogel, A., & Melisi, D. (2026). Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117036
Vancouver
Casalino S, Scarlato E, Cruz MC, Gerdes C, Sordo A, Quinzii A, et al. Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117036
BibTeX
@article{Casalino2026,
author = {Casalino, Simona and Scarlato, Enza and Cruz, Marina Crespo and Gerdes, Christoph and Sordo, Anna and Quinzii, Alberto and Zecchetto, Camilla and Messineo, Luisa and Tasselli, Ester and Mendo, Lucia and Saborowski, Anna and Bridgewater, John and Vogel, Arndt and Melisi, Davide},
title = {Futibatinib after non-covalent FGFR inhibitors in FGFR2-rearranged intrahepatic cholangiocarcinoma: clinical activity and resistance patterns},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2026.117036}
}
EUVIMED